Bimetallic FeCu-MOF derivatives as heterogeneous catalysts with enhanced stability for electro-Fenton degradation of lisinopril.

A bimetallic FeCu/NC core-shell catalyst, consisting in nanoparticles where zero-valent Fe and Cu atoms, slightly oxidized on their surface, are encapsulated by carbon has been successfully prepared by modifying the synthesis route of MIL(Fe)-88B. FeCu/NC possessed well-balanced textural and electrochemical properties. According to voltammetric responses, in-situ Fe(III) reduction to Fe(II) by low-valent Cu was feasible, whereas the high double-layer capacitance confirmed the presence of a great number of electroactive sites that was essential for continuous HO activation to OH via Fenton's reaction.

Mineralization of Acid Red 1 azo dye by solar photoelectro-Fenton-like process using electrogenerated HClO and photoregenerated Fe(II).

The degradation of Acid Red 1 (AR1) azo dye by solar photoelectro-Fenton-like (SPEF-like) process involving continuously electrogenerated hypochlorous acid (HClO) and photoregenerated Fe(II) to yield hydroxyl radicals, has been studied. The assays were made in a flow plant that included a filter-press cell equipped with a Ti|Ir-Sn-Sb oxide anode, to oxidize Cl ion to HClO, and a stainless-steel cathode. The cell was coupled to a compound parabolic collector (CPC) photoreactor, in series with a reservoir containing 6 L of solution.

Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. URTILOR study group.

Mizolastine, a new second-generation H1 receptor antagonist with additional anti-allergic properties, was compared with loratadine in 61 patients suffering from severe chronic idiopathic urticaria (CIU). In this double-blind study, patients were randomly allocated to receive either mizolastine 10 mg (n = 26) or loratadine 10 mg (n = 35) once-daily for 28 days. Both compounds were well tolerated, safe and efficacious.

QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine.

Background: Some H1 antihistamines are at risk for rare but severe dysrhythmias due to an effect on the ventricular repolarization.

Objective: To present an overview of the QT interval monitoring performed during the clinical development of mizolastine, a new selective second-generation H1 antihistamine.

Methods: The ECGs database analysis of clinical studies conducted in volunteers and patients is summarized and focused on the results of reported studies and studies specifically designed for the assessment of the effect of mizolastine on cardiac repolarization, through the QT interval measurements.

Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. RIPERAN Study Group.

Background: Mizolastine is a new, nonsedating antihistamine with additional anti-inflammatory properties, providing relief in allergic rhinitis and urticaria. The aim of this study was to determine the efficacy and safety of 10 mg o.d.

Lack of subsensitivity to mizolastine over 8-week treatment.

Mizolastine is a new, nonsedating antihistamine providing satisfactory symptom relief in allergic rhinitis and urticaria. The purpose of this study was to use the wheal and flare skin reactions model to assess the maintenance of the pharmacodynamic effect of mizolastine, administered for 2 months. This double-blind, parallel-group study involved 60 atopic patients randomly allocated, after a 1-week placebo run-in, to once-daily 10 mg mizolastine (n = 29) or placebo (n = 31) groups.

Efficacy and safety of mizolastine in seasonal allergic rhinitis. The Rhinase Study Group.

Background: Mizolastine is a new, nonsedating antihistamine under clinical investigation for treatment of allergic rhinitis and urticaria.

Objective: The purpose of this study was to determine the optimally active dose of once-daily mizolastine in seasonal allergic rhinitis.

Methods: This multicenter, double-blind, parallel study involved 494 patients randomly allocated to mizolastine (5, 10, or 15 mg) or placebo for 2 weeks.

Effects of acrivastine and terfenadine on skin reactivity to histamine.

The response to the histamine hydrochloride prick skin test was studied in 24 healthy volunteers who received, in random order and at least four days apart, acrivastine (8 mg), terfenadine (120 mg), and placebo. The tests were performed on either side of the back before and at the time of administration (single dose), then every 30 minutes for two hours, and every hour for the following four hours. Evaluation was based on the mean of two measurements of the surface area of the wheal-and-flare reaction accompanied by assessment of topical pruritus.

Purification of human IgG4 subclass with allergen-specific blocking activity.

Blocking antibodies (bAb) induced by allergen immunotherapy are restricted to the IgG1 and IgG4 subclasses, with IgG1 predominating early and IgG4 coming later. Study of IgG4 bAb has been limited, in part, by the absence of a method to purify IgG4. We describe a rapid immunoaffinity chromatographic method for the purification of that subclass from whole serum.

Blocking antibodies to inhalant allergens and asthma.

The mechanisms of specific immunotherapy are not still established. Among the lot of immunological changes, induced by immunotherapy, the increase of specific IgG 1, and then of IgG 4 antibodies, during the first months is well demonstrated. The skin-tests, the histamine-release and the human basophil degranulation are significantly decreased after incubation of allergen with the serum of desensitized patients.

Blocking activity of mite-specific IgG antibodies studied by skin tests.

The aim of the study was to determine whether IgG antibodies from patients on specific immunotherapy could inhibit skin test reactivity of allergens when mixed with them prior to testing. In a preliminary double-blind study, mite extracts were incubated with glycero-saline solution or non-specific IgG and used in testing 15 patients. Wheal and flare diameters produced with the two mite extracts did not differ significantly.

Blocking IgG antibodies after rush immunotherapy with mites.

The synthesis of blocking antibodies has been demonstrated in ten patients undergoing rush immunotherapy (R-IT) with mite extracts: basophil degranulation performed on washed cells (Allergolam technique) did not differ significantly before and 10.8 (+/- 6.8) months after R-IT.